Sage Bionetworks collaborates with AstraZeneca

The partnership will combine Sage Bionetworks’ expertise in computer models of disease genetics with AstraZeneca’s knowledge and expertise of oncology including access to data on AstraZeneca’s compounds.

The partnership will focus on investigating regulatory pathways among different cancers using large coherent cancer genomic datasets and predictive disease models developed at Sage Bionetworks.

The partnership will provide data-driven rationales for prioritizing therapeutic targets for developing new insights to improve cancer treatments, as well as potentially helping to identify cancer patient subpopulations that will most likely benefit from such treatments.